Literature DB >> 10514344

Role of baseline parameters in determining indirect pharmacodynamic responses.

Y N Sun1, W J Jusko.   

Abstract

Indirect Response Models account for the pharmacodynamics of numerous drugs which inhibit or stimulate the production (k(in)) or loss (k(out)) of the response variable (R). The dose and pharmacokinetics, capacity (S(max), I(max)), and potency (SC(50), IC(50)) factors of the Hill function incorporated in these models are the primary determinants of overall responsiveness. However, the initial or baseline value for the response (R(0) = k(in)/k(out)) should also be considered as an important factor for the net response. Using Indirect Response Model III (stimulation of input) as an example, the net area under the effect curve (AUEC(NET)) can be proportional to the R(0) values. Such a feature is demonstrated in this report by computer simulations, by examination of the integral of the simulated response vs time profiles, and with examples from the literature. Also shown is an adjustment of R(0) when the therapeutic agent is an endogenous substance. These analyses show that the role of R(0) and k(in) should not be overlooked as determinants of indirect responses and source of variation among subjects or patient groups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514344     DOI: 10.1021/js9901155

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

Review 1.  Nonlinear dynamics and chaos theory: concepts and applications relevant to pharmacodynamics.

Authors:  A Dokoumetzidis; A Iliadis; P Macheras
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  Approaches to handling pharmacodynamic baseline responses.

Authors:  Chantaratsamon Dansirikul; Hanna E Silber; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-04-30       Impact factor: 2.745

3.  Indirect pharmacodynamic models for responses with circadian removal.

Authors:  Vivaswath S Ayyar; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-01-29       Impact factor: 2.745

4.  Adjustment of endogenous concentrations in pharmacokinetic modeling.

Authors:  Alexander Bauer; Martin J Wolfsegger
Journal:  Eur J Clin Pharmacol       Date:  2014-10-03       Impact factor: 2.953

Review 5.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

6.  Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids.

Authors:  Vivaswath S Ayyar; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2019-06-13       Impact factor: 4.030

7.  Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats.

Authors:  Zhenling Yao; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

8.  Methods of utilizing baseline values for indirect response models.

Authors:  Sukyung Woo; Dipti Pawaskar; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-21       Impact factor: 2.745

9.  Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.

Authors:  Xinhui Chen; Sharon M Seifert; Jose R Castillo-Mancilla; Lane R Bushman; Jia-Hua Zheng; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.